Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study

World Journal of Biological Psychiatry

Volumn 14, Issue 4, 2013, Pages 268-281

  Casas, Miguel ^a   Rösler, Michael ^b   Sandra Kooij, J J ^c   Ginsberg, Ylva ^d   Ramos Quiroga, Josep Antoni ^a   Heger, Steffen ^e   Berwaerts, Joris ^f   Dejonckheere, Joachim ^g   Van Der Vorst, Erik ^h   Schäuble, Barbara ⁱ  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b SAARLAND UNIVERSITY   (Germany)

^c Program Adult ADHD   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Karolinska Institutet Center of Neurodevelopmental Disorders ^*  (Germany)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g SGS Medisearch International NV   (Belgium)

^h Janssen EMEA   (Belgium)

ⁱ JANSSEN CILAG GMBH   (Germany)

Author keywords

Adults; Attention deficit hyperactivity disorder; OROS methylphenidate; Randomized controlled trial; Treatment efficacy

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ADULT; AGITATION; ANOREXIA; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BACKACHE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL STATUS; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERHIDROSIS; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; OSMOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877633344     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.600333     Document Type: Article

References (35)

1. Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, et al. 2009. Effi cacy and safety of OROS methylphenidate in adults with attention-defi cit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, doseescalation study. J Clin Psychopharmacol 29:239-247.
2. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th edn, text revision. Washington, DC: American Psychiatric Association.
3. Barkley RA, Fischer M, Smallish L, Fletcher K. 2006. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45:192-202. (Pubitemid 43151524)
4. Baron RM, Kenny DA. 1986. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51:1173-1182.
5. Biederman J, Mick E, Faraone SV. 2000. Age-dependent decline of symptoms of attention defi cit hyperactivity disorder: impact of remission defi nition and symptom type. Am J Psychiatry 157:816-818. (Pubitemid 30249663)
6. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. 2006. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 59:829-835.
7. Biederman J, Mick EO, Surman C, Doyle R, Hammerness P, Michel E, et al. 2007. Comparative acute effi cacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 7:49.
8. Biederman J, Petty CR, Fried R, Kaiser R, Dolan CR, Schoenfeld S, et al. 2008. Educational and occupational underattainment in adults with attention-defi cit/hyperactivity disorder: a controlled study. J Clin Psychiatry 69:1217-1222.
9. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, et al. 2010. A randomized, 3-phase, 34-week, double-blind, long-term effi cacy study of osmotic-release oral system-methylphenidate in adults with attention-defi cit/hyperactivity disorder. J Clin Psychopharmacol 30:549-553.
10. Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F. 2003. The effi cacy of 2 different dosages of methylphenidate in treating adults with attention-defi cit hyperactivity disorder. Can J Psychiatry 48:546-554. (Pubitemid 37280044)
11. Buitelaar JK, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemel ä A, Konofal E, et al. 2009. Safety and tolerability of fl exible dosages of prolonged-release OROS methylphenidate in adults with attention-defi cit/hyperactivity disorder. Neuropsychiatr Dis Treat 5:457-466.
12. Conners C, Erhardt D, Sparrow E. 1999. Conners ' Adult ADHD Rating Scales (CAARS): Technical manual. North Tonawanda, NY: Multi-Health Systems.
13. De Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. 2008. The prevalence and effects of adult attention-defi cit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 65:835-842.
14. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. 2007. Cross-national prevalence and correlates of adult attention-defi cit hyperactivity disorder. Br J Psychiatry 190:402-409. (Pubitemid 46706952)
15. First M, Spitzer R, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. 1994. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York: New York State Psychiatric Institute, Biometrics Research.
16. Goodman DW. 2007. The consequences of attention-defi cit/hyperactivity disorder in adults. J Psychiatr Pract 13:318-327. (Pubitemid 47479448)
17. Guy W. 1976. HAMA Hamilton Anxiety Scale. In: Guy W, editor. ECDEU Assessment Manual, revised, pp. 194-198. Rockville, MD: US Department of Health and Human Services, Public Health Service-Alcohol, Drug Abuse, and Mental Health Administration.
18. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
19. Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, et al. 2007. Effi cacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-defi cit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 68:268-277. (Pubitemid 46362649)
20. Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, et al. 2005. The prevalence and effects of adult attention defi cit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 47:565-572. (Pubitemid 40847440)
21. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. 2006. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716-723. (Pubitemid 44464584)
22. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. 2004. Effi cacy and safety of methylphenidate in 45 adults with attention-defi cit/hyperactivity disorder: a randomized placebo-controlled double-blind cross-over trial. Psychol Med 34:973-982. (Pubitemid 39199967)
23. Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP. 2005. Internal and external validity of attention-defi cit hyperactivity disorder in a population-based sample of adults. Psychol Med 35:817-827. (Pubitemid 40873382)
24. Landgraf JM. 2007. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord 11:351-362.
25. Mannuzza S, Klein RG, Moulton 3rd JL. 2003. Persistence of attention-defi cit/hyperactivity disorder into adulthood: what have we learned from the prospective follow-up studies? J Atten Disord 7:93-100. (Pubitemid 38160973)
26. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemel ä A, Trott GE, et al. 2008. A randomized, placebo-controlled trial of 3 fi xed dosages of prolonged-release OROS methylphenidate in adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 63:981-989.
27. National Collaborating Centre for Mental Health 2008. Attention defi cit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. London: National Institute for Health and Clinical Excellence.
28. National Institute for Mental Health (NIMH) 1985. CGI (Clinical Global Impression Scale). Psychopharmacol Bull 21:843.
29. R ö sler M, Fischer R, Ammer R, Ose C, Retz W. 2009. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attentiondefi cit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120-129.
30. R ö sler M, Casas M, Konofal E, Buitelaar J. 2010. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 11:684-698.
31. Secnik K, Swensen A, Lage MJ. 2005. Comorbidities and costs of adult patients diagnosed with attention-defi cit hyperactivity disorder. Pharmacoeconomics 23:93-102. (Pubitemid 40194012)
32. Sheehan DV, Harnett-Sheehan K, Raj BA. 1996. The measurement of disability. Int Clin Psychopharmacol 11(Suppl 3):89-95. (Pubitemid 26373761)
33. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J. 2005. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attentiondefi cit/hyperactivity disorder. Biol Psychiatry 57:456-463. (Pubitemid 40311979)
34. Starr HL, Armstrong RB, Ma Y-W, Ascher S. 2010. Individualized dosing with OROS ® methylphenidate to optimize treatment in adults with attention-defi cit/hyperactivity disorder. Presented at the 2010 US Psychiatric & Mental Health Congress, Orlando, FL, USA.
35. Tarter R, Hegedus A. 1991. The Drug Use Screening Inventory: its application in the evaluation and treatment of alcohol and drug abuse. Alcohol Health Res World 15:65-75.